1.
P I : A / P G i o r g i a P A S T O R I N ǀ E L : W e i J i a n g G O H ǀ T M : S h u i Z O U ǀ M e n t o r : D r J u W e i W O N G
E X O P L E X s
Ta i l o r i n g Yo u r Tr a n s f e c t i o n N e e d s

2.
EXOPLEXs
An Nanoparticle
System
Drug cargo
Enlarged View
EXOPLEXs
• Small Molecules
• Peptides
• Plasmid
Value Proposition Drug Delivery

3.
EXOPLEXs
An Nanoparticle
System
Enlarged View
EXOPLEXs
High drug loading
capacity
Value Proposition Drug Delivery

4.
Targeted Drug
Delivery
Tumour cellsTumour cells delivered with
Anti-cancer Drug Cargo
Intravenous
Injection
Tumour SiteDrug loaded
EXOPLEXs
Targeting only Tumour Cells
Reduced
Tumour size
Value Proposition Drug Delivery

5.
Therapeutics
1
Cosmeceutical /
Dermatological Solutions
2 Transfection Kit for
Difficult-to-transfect cell
types
For Research Use
3
What we thought
5
What we brainstorm during LLP
What we thought Market Segments

6.
Research Assistants
PhDs
Post Doctoral
Research Fellows
Principle Investigators
Companies
Industry Liaison Office
Interviews
Medicine
Pharmacy
Engineering
Chemistry
Commercial
Interviews (by field)
6
Interviews Total 33

7.
Most Regulatory Oversight
Longest route to market
Most Requirement for data
Least Regulatory Oversight
Shortest route to market
Least Requirement for data
Transfection Kit for
Difficult-to-transfect
cell types
For Research Use
Cosmeceutical /
Dermatological Solutions
Therapeutics
1 2 3
Continue in the
background
No interest Beachhead Strategy
What we found Market Segments

8.
Transfection Kit for
Difficult-to-transfect
cell types
For Research Use
Cosmeceutical /
Dermatological Solutions
Therapeutics
1 2 3
Continue in the
background
No interest Beachhead Strategy
8
Big Pharma
Therapeutics Company
Cosmetic Companies Laboratory End UsersCustomers
From B2B to B2C
What we found Customers

9.
EXOPLEXs
Genetic Material
Enlarged View
EXOPLEXs
• Plasmid
• siRNA
• shRNA
Beachhead Strategy
Transfecting Difficult-to-Transfect Cells

10.
EXOPLEXs
Genetic Material
Enlarged View
EXOPLEXs
Beachhead Strategy
Transfecting Difficult-to-Transfect Cells

11.
11
Single Step
Transfection
Target cells
(Eg. Fat cells, Blood Cells,
Skin cells, Stem Cells)
Cells expressing GFP
EXOPLEXs
With plasmid
Transfecting Difficult-to-Transfect Cells
Beachhead Strategy
Transfecting Difficult-to-Transfect Cells
* GFP: Green Fluorescent Protein

12.
12
CAGR 7.1% from 2009 to 2016
What we found Market Sizing
$183.6
Million
Transfection Reagents Market
Transfection Research Market
$30 Billion
Drug Delivery Market
$348 Million
1. Frost & Sullivan, 2010, Global Transfection Markets.
2. Frost & Sullivan, 2016, Nanotechnology for Effective Drug Delivery

13.
13
EaseofUse
Efficacy *size of circle: Cost Effectiveness
EXOPLEXs
Lipofectamine Effectene
PEI
Electroporation
Combination of
methods
Viral delivery
Transfection Research
What we found Competitive Landscape

14.
14
EXOPLEXs
Sales
(Transfection Kit)
Licensing
What we thought What we found
Licensing
EXOPLEXs
Lab End UsersResearch Kit
Companies
Research Kit
Companies
What we found Business Model

15.
15
What we found Channels
Direct Sales
Distributorships
Time
Collaborations • Efficacy Data, Publications
• Product Support
• Small scale manufacture
• Bespoke services
• OEM
• Sales force

16.
1. Targeting &
Minimal
collateral
damage
2. Improved cell
delivery
3. Biocompatible
4. Avert patent
cliff
1. Universities
2. Pharma companies
3. Therapeutic
companies
4. Drug Delivery
companies
5. Cosmetic
companies
Production of:
• Efficacy data
• Safety data
• Intellectual
property
• Trained
laboratory users
• Raw materials
• Equipment
• Universities
• Government
(Grants)
1. In-house development of single chemotherapeutic
2. In-house development of EXOPLEXs as transfection agent
3. In-house development of EXOPLEXs as a cosmetic agent
4. Licencing for other uses
Value driven:
1. R & D costs
2. Trained personnel costs
3. Raw materials
4. Patent development
1. Outreach via
publications,
workshops and
conferences
2. Continuous feedback
with interested parties
to fine tune EXOPLEXs
platform to their use
• Single sided niche
market
• B2B model
When we first started Business Model Canvas

17.
Key Partners Key Activities Value
Proposition
Key Resources
Customer
Relationships
Channels
Customer
Segments
Cost Structure Revenue
Streams
1. Publications
2. Efficacy data
3. Comparison
data
• Transfecting
Difficult-to-
Transfect cells
• Improved user
experience
• Increased
research
efficiency
• Co-
development/
collaboration
with
innovators &
early adopters
• Direct
• Academic and
research labs
focusing tissue
labs
• Primary cell
lines
• Skin, fat,
neurons,
stem cells
• Intellectual
Property
• Trained lab
personnel
• Keep costs down, asset light by
staying affiliated to NUS
• Currently exploring other revenue
streams, ie direct sales and co-
development with other companies.
After 10 weeks Business Model Canvas

18.
18
Transfecting difficult to
transfect Cells
Drug Delivery
Clinical Applications
Gene Therapy
Peptide-based Delivery
Small Molecule Delivery
Beachhead Strategy
• Revenue Generation
• Direct sales
• Licensing
• Distributorships
Long Term Strategy
• Revenue Generation
• Licensing
• Co-development
2016: $183.6 Million1 2020: $30 Billion
1. Frost & Sullivan, 2010, Global Transfection Markets.
2. Frost & Sullivan, 2016, Nanotechnology for Effective Drug Delivery
Time (Years)
Difficulty
Roadmap for the Future

19.
19
What we have now What we will do next
1. Provisional Patent
2. Efficacy data
1. More R & D for MVP
2. Publications
3. Find potential
Collaborators (Labs)
4. Applications for Grants
(POC)
Next Steps

20.
20
Wei Jiang GOH
Principle Investigator
Department of Pharmacy
Entrepreneurial Lead
PhD-MBA Student
Department of Pharmacy
Team Member
PhD Student
Department of Pharmacy
A/P Giorgia PASTORIN Shui ZOU
The Team
Team Mentor
Dr Ju Wei Wong

21.
21
Thank You
E X O P L E X s

22.
E X O P L E X s
Strategy
Transfection Kit
• Difficult-to-transfect cells
Drug delivery platform
• Small molecules
• Peptides
• Genetic material
Small Scale
Manufacturing
Licensing
Licensing
Co-Development
Direct Sales
Sales & Distributorship
Research Lab End
Users
Research Reagent
Companies
Generics Companies
Delivery to difficult to reach
cells
• Neurodegenerative diseases
• Diabetes
Partnership with emerging
biotech companies
• Potential NDAs
Search for off-patent drug for
averting patent cliff
Pharma Companies
Biotech Companies
Strategy Revenue Model Customer
*Beachhead strategy
2020: $30 Billion
2016: $183.6 Million
*Frost & Sullivan